Revenue
No reported data
Jade Biosciences, Inc. (JBIO)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $93.1M | $53.2M | $64.2M | $38.6M | $15.0M | $7.9M |
| Operating expenses | $113.5M | $74.6M | $81.4M | $53.2M | $23.0M | $8.9M |
| Operating income | −$113.5M | −$74.6M | −$81.4M | −$53.2M | −$23.0M | −$8.9M |
| Net income | −$127.4M | −$69.6M | −$75.5M | −$51.5M | −$23.0M | −$9.6M |
| Basic EPSper diluted share | -$3.19 | -$2.44 | -$2.87 | -$2.10 | -$1.87 | -$40.31 |
| Diluted EPSper diluted share | -$3.19 | -$2.44 | -$2.87 | -$2.10 | -$1.87 | -$40.31 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 16, 2025Form 4 | Frohlich TomChief Executive Officer | BuyCommon Stock | 6.0K | $7.40 | $44.4K | 6.0K |